EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Acorda Therapeutics's Enterprise Value is $161.6 Mil.
Acorda Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-263.8 Mil. Therefore, Acorda Therapeutics's EV-to-EBIT for today is -0.61.
The historical rank and industry rank for Acorda Therapeutics's EV-to-EBIT or its related term are showing as below:
ACORQ'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1024.09 Med: -0.94 Max: 191.36
Current: -0.61
During the past 13 years, the highest EV-to-EBIT of Acorda Therapeutics was 191.36. The lowest was -1024.09. And the median was -0.94.
ACORQ's EV-to-EBIT is ranked worse than 100% of 670
companies
in the Drug Manufacturers industry
Industry Median: 17.115
vs ACORQ: -0.61
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Acorda Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $179.7 Mil.
Acorda Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-263.8 Mil. Acorda Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -146.85%.
Acorda Therapeutics EV-to-EBIT Historical Data
The historical data trend for Acorda Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Acorda Therapeutics's EV-to-EBIT
For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acorda Therapeutics's EV-to-EBIT Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Acorda Therapeutics's EV-to-EBIT falls into.
Acorda Therapeutics EV-to-EBIT Calculation
Acorda Therapeutics's EV-to-EBIT for today is calculated as:
Acorda Therapeutics's current Enterprise Value is $161.6 Mil.
Acorda Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-263.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Acorda Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $179.7 Mil.
Acorda Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-263.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acorda Therapeutics EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Acorda Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Acorda Therapeutics (Acorda Therapeutics) Business Description
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACORQ has been successfully added to your 